BARCELONA--1 Sep--PRNewswire-AsiaNet/InfoQuest
A new analysis from the JUPITER study showed that CRESTOR(R) (rosuvastatin) 20mg reduced the composite primary end point of major cardiovascular (CV) events (combined risk of myocardial infarction, stroke,arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p